Groupe Actéo (Théolaur Peintures) welcomes GENEO and Bpifrance
The founders of Groupe Actéo (Théolaur Peintures) have opened the capital to GENEO Capital Entrepreneur and Bpifrance.
Actéo, which will celebrate its 200th anniversary in 2025, is an independent, family-owned group specializing in the production and distribution of building and decorative paints for a clientele of building professionals. Production is handled by its subsidiary Theolaur, which operates two production sites in the Hauts-de-France and Occitanie regions of France. Distribution is handled by its subsidiary Théodore Maison de Peinture, which runs its own network of 70 sales outlets, which is constantly expanding. In addition to its specialized outlets, the group’s products are sold by over 100 independent distributors throughout France. Groupe Actéo records annual sales of approximately US$100 million.
GENEO Capital Entrepreneur is an investment and support company, created by entrepreneurs and families, that supports SMEs and ETIs in their long-term development projects.
Bpifrance is a French public investment bank dedicated to financing and developing businesses. It has become the one-stop shop for entrepreneurs, with a comprehensive toolbox offered to customers through 50 local branches.
Oaklins’ team in France led a competitive process in which it acted as the exclusive sell-side financial advisor to support Actéo’s shareholders in their choice of the best partner to pursue its growth.
Hugo Robardey and Laurent Letort
CEO, Groupe Actéo
Contáctese con el equipo de la transacción
Transacciones relacionadas
Den Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Conozca másXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Conozca másT BAILEY has been acquired by Saothair Capital Partners
Saothair Capital Partners has completed the acquisition of T BAILEY. This transaction will provide T BAILEY with the resources needed to continue delivering exceptional service to its customers and strengthen its position in the marketplace.
Conozca más